Celgene: Still Upside Left After Deal?

Summary

Yesterday, Bristol-Myers Squibb announced a deal to acquire Celgene. This was biggest deal in the biotech sector in many, many years.

While Celgene has rallied over 25% since the merger, the shares still do not reflect the true value of the announced transaction.

We take a detailed look at this.

Looking for more? I update all of my investing ideas and strategies to members of The Biotech Forum. Start your free trial today ยป

"Some people talk in their sleep. Lecturers talk while other people sleep." - Albert Camus

Yesterday we saw the largest acquisition deal in the biotech industry in many, many years announced. Bristol-Myers Squibb (BMY) agreed to acquire biotech stalwart Celgene (CELG) for just under $75 billion before the bell Thursday. This would be the largest buyout in the sector in many, many years.

Celgene's shares are up over 25% in trading since the deal was announced. However, the stock is not close to Bristol's buyout offer. I have received myriad inquiries on that this morning, so I thought I would provide a quick analysis of the offer and what I am doing with my shares in Celgene. That follows in the paragraphs below.

READ FULL ARTICLE HERE